Recursion Pharmaceuticals (RXRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Recursion Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$3.63+0.19(0.06%)Market closed

Market Cap

$2.04B

P/S

37.2x

P/B

2.2x

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

How this company scores

WeakMetricSide Score: 46/100

Grade capped at D — Interest coverage below 1× (-440.1x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (17/25); weakest: Cash & Earnings Quality (6/25).

Profitability15/25

Growth8/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality6/25

Strengths

Low leverageProfit converts from growthImproving leverageNet cash position

Grade capped at D

Interest coverage below 1× (-440.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 37.2x5y range 22.6x – 215.3x

Currently near its 19-quarter median.

P/B · 2.2x5y range 1.5x – 6.2x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.04B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $54.85M
Q. Revenue: $7.67M
TTM EBITDA: $-420.76M
TTM Op. Income: $-544.01M
Q. Op. Income: $-134.97M
TTM Net Income: $-518.88M
Q. Net Income: $-131.00M
EPS: $-0.25
Shares Out.: $532.46M

$54.85M in TTM revenue declined 15.1% YoY, reaching $7.67M last quarter. TTM EBITDA of $-420.76M and TTM operating income of $-544.01M show growth is flowing through to the bottom line. However, net income is negative at $518.88M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: -49.8%
EBITDA Margin: -1522.8%
Op. Margin: -1759.7%
Net Margin: -1708.0%

Op. margin of -1759.7% is down 842.9% YoY — costs are rising relative to revenue. Net margin at -1708.0% and gross margin of -49.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 92% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 37.2x
P/B Ratio: 2.2x

P/S of 37.2x and P/B of 2.2x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.21B
Cash: $545.68M
Long-Term Debt: $4.75M
Book Value: $915.00M
D/E Ratio: 0.0
Debt/EBITDA: N/A

With $1.21B in assets and $4.75M in long-term debt, D/E is 0.0and book value is $915.00M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-105.95M
TTM Free Cash Flow: $-352.27M
FCF Margin: -642.2%
FCF / Net Income: 0.7

TTM FCF of $-352.27M on $-105.95M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 11% — a weakening trend.